Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cathay Capital, a China-US-French PE Firm, Invests in Cenexi

publication date: Jul 9, 2015
Cathay Capital Private Equity has invested in Cenexi Group, a French pharmaceutical contract manufacturing organization. Cathay's goal is to help Cenexi become a global company, adding US operations. Cathay, with offices in Shanghai, Beijing, New York and Paris, specializes in cross-border growth, either through internal expansion or through M&A. Cenexi was spun out of Roche in 2008 and specializes in making high value-added sterile products. The size of the investment was not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital